|
CAS No. | 160807-49-8 |
Chemical Name: | INDIRUBIN-3'-MONOXIME |
Synonyms: | Indirubin-3'INDIRUBIN-3'-OXIME;Indirubine-3'-oxime;INDIRUBIN-3'-MONOXIME;INDIRUBIN-3’-MONOOXIME;3-[1,3-DIHYDRO-3-(HYDROXYIMINO)-2H-INDOL-2-YLIDENE]-1,3-DIHYDRO-2H-INDOL-2-ONE |
CBNumber: | CB1325944 |
Molecular Formula: | C16H11N3O2 |
Formula Weight: | 277.28 |
MOL File: | 160807-49-8.mol |
|
|
|
|
INDIRUBIN-3'-MONOXIME Property |
|
|
storage temp. : |
Store at RT |
|
solubility : |
DMSO: >10 mg/mL
|
|
|
Stability:: |
Light Sensitive |
|
|
INDIRUBIN-3'-MONOXIME Chemical Properties,Usage,Production |
Chemical Properties
Dark Red Solid |
|
Usage
A potent inhibitor of GSK-3? (IC50=22nM). Also inhibits CDK1 (IC50=180nM) and CDK (IC50=100nM). It reversibly arrests asynchronous HBL-100 cells at G2. It induces apoptosis in the mammary carcinoma cell line MCF-7 (10üM). |
|
Biological Activity
Protein kinase inhibitor: inhibits cyclin-dependent kinases (IC 50 = 0.18-3.33 μ M) and GSK-3 β (IC 50 = 0.19 μ M). Inhibits CDK5- and GSK-3 β -mediated tau phosphorylation, a process over-active in Alzheimer disease states. Also inhibits AMPK, LCK and SGK. Induces cell cycle arrest and inhibits cell proliferation. |
|
|
INDIRUBIN-3'-MONOXIME Preparation Products And Raw materials |
Raw materials
|
Preparation Products
|
INDIRUBIN-3'-MONOXIME Suppliers Global( 33)Suppliers |
|
|
|
|
160807-49-8(INDIRUBIN-3'-MONOXIME)Related Search: |
Indirubin
1-METHYL-BIO
(2'Z,3'E)-6-BROMOINDIRUBIN-3'-OXIME
INDIRUBIN-3'-MONOXIME-5-SULPHONIC ACID
INDIRUBIN-3'-MONOXIME, 5-IODO-
(2'Z,3'E)-6-BROMOINDIRUBIN-3'-ACETOXIME
INDIRUBIN-3'-MONOXIME
|
3-[1,3-DIHYDRO-3-(HYDROXYIMINO)-2H-INDOL-2-YLIDENE]-1,3-DIHYDRO-2H-INDOL-2-ONE
Apoptosis and Cell Cycle
BioChemical
Cell Biology
Cell Signaling and Neuroscience
Cell Cycle
Cell Cycle Regulators
160807-49-8
INDIRUBIN-3'-MONOXIME
INDIRUBIN-3'-OXIME
Indirubine-3'-oxime
Aromatic Hydrazides, Hydrazines, Hydrazones and Oximes
Inhibitors
Protein Kinase
INDIRUBIN-3’-MONOOXIME
Intracellular Signaling
Indirubin-3'
|
Copyright 2016 © ChemicalBook. All rights reserved |